JP6261560B2 - 抗微生物性の短リポペプチド - Google Patents

抗微生物性の短リポペプチド Download PDF

Info

Publication number
JP6261560B2
JP6261560B2 JP2015501713A JP2015501713A JP6261560B2 JP 6261560 B2 JP6261560 B2 JP 6261560B2 JP 2015501713 A JP2015501713 A JP 2015501713A JP 2015501713 A JP2015501713 A JP 2015501713A JP 6261560 B2 JP6261560 B2 JP 6261560B2
Authority
JP
Japan
Prior art keywords
lysine
formulation
skin
proline
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015501713A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015512386A (ja
JP2015512386A5 (enExample
Inventor
ジャン，リジュアン
カーマイケル，ロビン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helix Biomedix Inc
Original Assignee
Helix Biomedix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helix Biomedix Inc filed Critical Helix Biomedix Inc
Publication of JP2015512386A publication Critical patent/JP2015512386A/ja
Publication of JP2015512386A5 publication Critical patent/JP2015512386A5/ja
Application granted granted Critical
Publication of JP6261560B2 publication Critical patent/JP6261560B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Birds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2015501713A 2012-03-20 2013-03-07 抗微生物性の短リポペプチド Expired - Fee Related JP6261560B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261613212P 2012-03-20 2012-03-20
US61/613,212 2012-03-20
PCT/US2013/029696 WO2013142088A1 (en) 2012-03-20 2013-03-07 Short antimicrobial lipopeptides

Publications (3)

Publication Number Publication Date
JP2015512386A JP2015512386A (ja) 2015-04-27
JP2015512386A5 JP2015512386A5 (enExample) 2016-04-07
JP6261560B2 true JP6261560B2 (ja) 2018-01-17

Family

ID=47901428

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015501713A Expired - Fee Related JP6261560B2 (ja) 2012-03-20 2013-03-07 抗微生物性の短リポペプチド

Country Status (18)

Country Link
US (1) US9278994B2 (enExample)
EP (1) EP2827907B1 (enExample)
JP (1) JP6261560B2 (enExample)
KR (1) KR20140136494A (enExample)
CN (2) CN107080831A (enExample)
AR (1) AR090439A1 (enExample)
AU (1) AU2013235692B2 (enExample)
CA (1) CA2864179A1 (enExample)
DK (1) DK2827907T3 (enExample)
ES (1) ES2729237T3 (enExample)
MX (1) MX2014011290A (enExample)
MY (1) MY163100A (enExample)
PL (1) PL2827907T3 (enExample)
RU (2) RU2627648C2 (enExample)
SG (2) SG10201607784VA (enExample)
TW (1) TWI541254B (enExample)
WO (1) WO2013142088A1 (enExample)
ZA (1) ZA201405950B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6906274B2 (ja) * 2014-06-30 2021-07-21 ロート製薬株式会社 外用組成物、眼科用組成物、抗菌剤、及び抗菌方法
WO2016002767A1 (ja) * 2014-06-30 2016-01-07 ロート製薬株式会社 外用組成物
US10660979B2 (en) * 2015-08-26 2020-05-26 The General Hospital Corporation System and method for electrical control of bacteria
KR101855170B1 (ko) * 2015-11-18 2018-05-08 (주)노바셀테크놀로지 신규 항균 펩타이드 및 그의 용도
CN109320585B (zh) * 2018-09-06 2021-10-26 南方医科大学 一种具有专一性抗痤疮丙酸杆菌作用及抗炎作用的短脂肽
CA3112268A1 (en) * 2018-09-12 2020-03-19 The Governing Council Of The University Of Toronto Indole-oxadiazole compounds and their therapeutic use
CN111035764B (zh) * 2018-10-14 2021-09-07 深圳市健元医药科技有限公司 一种治疗类风湿性关节炎的组合物及其制备方法
CN110279844A (zh) * 2019-01-31 2019-09-27 浙江星杭泰乐生物医药有限公司 人工合成抗菌肽在制备抑菌消炎祛痘化妆品或外用药物制剂中的应用及抑菌消炎祛痘组合物
CN111303242B (zh) * 2020-02-27 2022-04-26 广州领晟医疗科技有限公司 一种KdPT的修饰肽
KR102163568B1 (ko) * 2020-08-21 2020-10-07 주식회사 비드테크 지방산 항균펩타이드 및 이를 함유하는 항균 조성물
MX2023003595A (es) * 2020-09-29 2023-04-05 Unilever Ip Holdings B V Una composicion para el cuidado personal que comprende aminoacidos.
US11793746B2 (en) * 2020-10-01 2023-10-24 Chanda Zaveri Intense skin hydration systems and methods
CN112679576B (zh) * 2020-11-06 2022-09-20 黄石瀚海新材料科技有限公司 抗菌脂肽、抗菌脂肽水凝胶制备方法及其应用
CN121471309B (zh) * 2026-01-05 2026-07-07 中国科学院理化技术研究所 一种菌群友好型选择性抗真菌肽hri及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69230500D1 (de) * 1991-10-28 2000-02-03 Cytran Ltd Pharmazeutische Dipeptid Zusammensetzungen und Verwendungsmethoden.
JP3273314B2 (ja) * 1998-08-12 2002-04-08 独立行政法人農業生物資源研究所 抗菌ペプチド及びこれを有効成分とする抗菌剤
US6492326B1 (en) 1999-04-19 2002-12-10 The Procter & Gamble Company Skin care compositions containing combination of skin care actives
DE10106852A1 (de) 2001-02-14 2002-09-05 T Luger Entzündungshemmende Verbindungen
SE0300207D0 (sv) * 2003-01-29 2003-01-29 Karolinska Innovations Ab New use and composition
US7671011B2 (en) * 2003-06-19 2010-03-02 Yeda Research & Development Co. Ltd. Antimicrobial and anticancer lipopeptides
KR101045658B1 (ko) * 2003-11-17 2011-07-01 쎄데르마 테트라펩티드 및 트리펩티드 혼합물을 포함하는 조성물
FR2870244B1 (fr) * 2004-05-11 2011-01-07 Centre Nat Rech Scient Conjugues dipeptidiques antagonistes de l'alpha-msh
DE102004055541A1 (de) * 2004-11-17 2006-05-18 Henkel Kgaa Kosmetische und dermatologische Zusammensetzungen zur Behandlung reifer Haut
US20100215726A1 (en) * 2009-02-25 2010-08-26 Peter Thomas Roth Compositions for Diminishing the Appearance of Wrinkles
CN102329375A (zh) * 2011-09-30 2012-01-25 中国药科大学 一组末端酰胺化的抗菌肽

Also Published As

Publication number Publication date
AU2013235692B2 (en) 2016-12-08
AR090439A1 (es) 2014-11-12
PL2827907T3 (pl) 2019-08-30
JP2015512386A (ja) 2015-04-27
ES2729237T3 (es) 2019-10-31
TWI541254B (zh) 2016-07-11
TW201339176A (zh) 2013-10-01
CN107080831A (zh) 2017-08-22
CA2864179A1 (en) 2013-09-26
RU2627648C2 (ru) 2017-08-09
CN104379177B (zh) 2017-07-04
SG11201405244RA (en) 2014-10-30
KR20140136494A (ko) 2014-11-28
MY163100A (en) 2017-08-04
US20150080291A1 (en) 2015-03-19
SG10201607784VA (en) 2016-11-29
CN104379177A (zh) 2015-02-25
DK2827907T3 (da) 2019-06-11
AU2013235692A1 (en) 2014-09-25
EP2827907A1 (en) 2015-01-28
RU2014142038A (ru) 2016-05-10
EP2827907B1 (en) 2019-03-06
ZA201405950B (en) 2017-08-30
RU2017127273A (ru) 2019-02-04
WO2013142088A1 (en) 2013-09-26
HK1204453A1 (en) 2015-11-20
US9278994B2 (en) 2016-03-08
MX2014011290A (es) 2014-10-13

Similar Documents

Publication Publication Date Title
CN104379177B (zh) 短抗微生物脂肽
US8871716B2 (en) Use of antimicrobial peptides in regeneration of skin cells
JP6230566B2 (ja) 皮膚化粧用組成物におけるオリゴマーバイオサーファクタント
EP2245045B1 (en) Peptide derivatives useful in the treatment, care or cleansing of the skin, mucosae, scalp or nails
CN105120884B (zh) 用于促进伤口愈合的短生物活性肽
KR20230048515A (ko) 천연 스킨케어 조성물
EP3329905A1 (en) Topical cosmetic compositions comprising an oligopeptide against anti-aging of the skin
WO2002040529A2 (en) Diastereomeric peptides and pharmaceutical compositions comprising them
EP3613438B1 (en) Conjugate of isotretinoin and peptide
HK1204453B (en) Short antimicrobial lipopeptides
KR20180125419A (ko) 이소트레티노인과 펩타이드의 결합체
US20220071921A1 (en) Compounds for preventing and treating skin or mucosal affections having an inflammatory component
JPWO2012157674A1 (ja) 環状ペプチド化合物またはその薬理的に許容される塩、その製造方法、及びその用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170214

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170523

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170613

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170911

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171122

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171205

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171212

R150 Certificate of patent or registration of utility model

Ref document number: 6261560

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees